232 related articles for article (PubMed ID: 17675499)
1. O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes.
Ninkovic T; Hanisch FG
J Immunol; 2007 Aug; 179(4):2380-8. PubMed ID: 17675499
[TBL] [Abstract][Full Text] [Related]
2. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.
Madsen CB; Petersen C; Lavrsen K; Harndahl M; Buus S; Clausen H; Pedersen AE; Wandall HH
PLoS One; 2012; 7(11):e50139. PubMed ID: 23189185
[TBL] [Abstract][Full Text] [Related]
3. Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine.
Hanisch FG; Ninkovic T
Curr Protein Pept Sci; 2006 Aug; 7(4):307-15. PubMed ID: 16918445
[TBL] [Abstract][Full Text] [Related]
4. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
5. Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes.
Ninkovic T; Kinarsky L; Engelmann K; Pisarev V; Sherman S; Finn OJ; Hanisch FG
Mol Immunol; 2009 Nov; 47(1):131-40. PubMed ID: 19007994
[TBL] [Abstract][Full Text] [Related]
6. O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells.
Hanisch FG; Schwientek T; Von Bergwelt-Baildon MS; Schultze JL; Finn O
Eur J Immunol; 2003 Dec; 33(12):3242-54. PubMed ID: 14635032
[TBL] [Abstract][Full Text] [Related]
7. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
[TBL] [Abstract][Full Text] [Related]
8. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells.
Hiltbold EM; Alter MD; Ciborowski P; Finn OJ
Cell Immunol; 1999 Jun; 194(2):143-9. PubMed ID: 10383817
[TBL] [Abstract][Full Text] [Related]
9. Design of a MUC1-based cancer vaccine.
Hanisch FG
Biochem Soc Trans; 2005 Aug; 33(Pt 4):705-8. PubMed ID: 16042579
[TBL] [Abstract][Full Text] [Related]
10. Making the most of mucin: a novel target for tumor immunotherapy.
Barratt-Boyes SM
Cancer Immunol Immunother; 1996 Nov; 43(3):142-51. PubMed ID: 9001567
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody BW835 defines a site-specific Thomsen-Friedenreich disaccharide linked to threonine within the VTSA motif of MUC1 tandem repeats.
Hanisch FG; Stadie T; Bosslet K
Cancer Res; 1995 Sep; 55(18):4036-40. PubMed ID: 7545084
[TBL] [Abstract][Full Text] [Related]
12. Expression of aberrantly glycosylated tumor mucin-1 on human DC after transduction with a fiber-modified adenoviral vector.
van Leeuwen EB; Cloosen S; Senden-Gijsbers BL; Agervig Tarp M; Mandel U; Clausen H; Havenga MJ; Duffour MT; García-Vallejo JJ; Germeraad WT; Bos GM
Cytotherapy; 2006; 8(1):24-35. PubMed ID: 16627342
[TBL] [Abstract][Full Text] [Related]
13. The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma.
Saeland E; van Vliet SJ; Bäckström M; van den Berg VC; Geijtenbeek TB; Meijer GA; van Kooyk Y
Cancer Immunol Immunother; 2007 Aug; 56(8):1225-36. PubMed ID: 17195076
[TBL] [Abstract][Full Text] [Related]
14. Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA.
Dörfel D; Appel S; Grünebach F; Weck MM; Müller MR; Heine A; Brossart P
Blood; 2005 Apr; 105(8):3199-205. PubMed ID: 15618468
[TBL] [Abstract][Full Text] [Related]
15. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.
Stepensky D; Tzehoval E; Vadai E; Eisenbach L
Clin Exp Immunol; 2006 Jan; 143(1):139-49. PubMed ID: 16367945
[TBL] [Abstract][Full Text] [Related]
16. Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity.
Irimura T; Denda K; Iida Si; Takeuchi H; Kato K
J Biochem; 1999 Dec; 126(6):975-85. PubMed ID: 10578046
[TBL] [Abstract][Full Text] [Related]
17. Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase from milk or mammary carcinoma cells.
Stadie TR; Chai W; Lawson AM; Byfield PG; Hanisch FG
Eur J Biochem; 1995 Apr; 229(1):140-7. PubMed ID: 7744025
[TBL] [Abstract][Full Text] [Related]
18. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
[TBL] [Abstract][Full Text] [Related]
19. Peptide mimics of a tumor antigen induce functional cytotoxic T cells.
Apostolopoulos V; Lofthouse SA; Popovski V; Chelvanayagam G; Sandrin MS; McKenzie IF
Nat Biotechnol; 1998 Mar; 16(3):276-80. PubMed ID: 9528009
[TBL] [Abstract][Full Text] [Related]
20. N-acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts.
Nishimori I; Perini F; Mountjoy KP; Sanderson SD; Johnson N; Cerny RL; Gross ML; Fontenot JD; Hollingsworth MA
Cancer Res; 1994 Jul; 54(14):3738-44. PubMed ID: 8033093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
